908 Devices Inc. Q2 FY2025 earnings call

Key Points

• Delivered 14% revenue growth, with adjusted EBITDA loss improving over 45% year-over-year and 15% quarter-over-quarter.
• Three strategic focus areas: 1) Increasing adoption of devices for public health/safety, with 164 devices placed in Q2 including record XplorIR units. 2) Advancing next-gen analytical tools with the launch of VipIR, a 3-in-1 handheld chemical analyzer. 3) Strengthening financial position through manufacturing transfer to Danbury, acquisition of KAF Manufacturing, and reducing operating expenses via facility and headcount cuts.

Initiatives

• Completed manufacturing transfer of MX908 to Danbury, CT; acquired KAF Manufacturing to secure supply chain and improve margins; signed a 3-year $6.6 million supply agreement.

Revenue from continuing operations was $13 million, an increase of 14% over the prior year period. Growth was driven by strong device sales, with mass spec devices accounting for roughly 60% of revenue and FKR products making up 40%. Handheld product and service revenue was $12.5 million for the second quarter 2025, up 13% from the prior year period. Recurring revenue, consisting of consumables, accessories and service revenue, represented 36% of total revenues this quarter and was $4.7 million. Gross profit was $6.4 million for the second quarter of 2025 compared to $6.2 million for the prior year period. Adjusted gross profit was $7.3 million for the second quarter of 2025 compared to $6.7 million for the prior year period.

2025 Guidance

• Revenue from continuing operations expected in the range of $54 million to $56 million, representing growth of 13% to 17% over full year 2024.
• Target adjusted EBITDA positivity in Q4 2025, supported by Q4 revenue projection of approximately $17 million, anticipated gross margin expansion, and lower operating costs.

2026 Outlook

• Revenue growth to accelerate above 20% driven by expanding handheld adoption, launching next-generation products, and scaling U.S. government programs. Adjusted gross margins expected to expand further in 2026 with manufacturing consolidation.

Forward-looking statements involve material risks and uncertainties, including those related to market conditions, competition, regulatory changes, and supply chain disruptions. Additional information regarding these risks appears in the company's Form 10-K and other SEC filings.

Q: Are federal funding items showing in the order book or sales funnel?

A: There is some visibility with a continuing resolution, but long-term drivers exist with defense and DHS budget increases. Tailwinds from legislation like the One Big Beautiful Bill and NATO's increased defense spending are favorable.

Q: Early uptake of VipIR?

A: VipIR, launched in July, fits customs organization needs, has early positive feedback, and is expected to move from pilot to enterprise in 2026. It addresses challenges of interdicting dangerous materials while facilitating trade.

Q: Runway for XplorIR growth from new funding?

A: XplorIR saw strong Q2 performance, majority orders funded by the assistant to firefighters grant program. There's a $1.7 billion grant funding increase, with diverse orders supporting sustained growth.

Q: AVCAD phasing and revenue opportunity?

A: AVCAD could start shipments in 2026, with an approximate $10 million+ annual revenue opportunity. Timing depends on receiving the full rate production award, and it leverages the company's mass spec technology.

Q: Manufacturing of new products in Danbury?

A: Yes, new products including MX908 2.0 are manufactured in Danbury. Minimal CapEx is needed as the facility is consolidated, leveraging existing setup and acquired assets for margin improvement.